Virtu Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1M Buy
+285,829
New +$914K 0.04% 308
2025
Q3
Sell
-12,555
Closed -$22K 1768
2025
Q2
$22K Buy
+12,555
New +$31.2K ﹤0.01% 1245
2025
Q1
Sell
-63,276
Closed -$468K 1674
2024
Q4
$468K Buy
+63,276
New +$587K 0.02% 527
2024
Q3
Sell
-94,099
Closed -$755K 1614
2024
Q2
$755K Buy
+94,099
New +$1.01M 0.05% 353
2023
Q3
Sell
-21,851
Closed -$154K 1577
2023
Q2
$154K Buy
+21,851
New +$156K 0.01% 898
2021
Q2
Sell
-42,480
Closed -$1.34M 1772
2021
Q1
$1.34M Buy
42,480
+35,981
+554% +$1.49M 0.1% 183
2020
Q4
$302K Sell
6,499
-12,212
-65% -$485K 0.03% 639
2020
Q3
$616K Sell
18,711
-1,120
-6% -$34.3K 0.11% 233
2020
Q2
$544K Buy
+19,831
New +$652K 0.06% 346
2019
Q4
Sell
-11,814
Closed -$215K 1627
2019
Q3
$215K Buy
+11,814
New +$261K 0.02% 933
2019
Q2
Sell
-10,385
Closed -$99K 1640
2019
Q1
$99K Buy
+10,385
New +$101K 0.01% 1131
2018
Q4
Sell
-60,812
Closed -$684K 1758
2018
Q3
$684K Buy
+60,812
New +$863K 0.04% 470
2018
Q1
Sell
-22,861
Closed -$183K 2260
2017
Q4
$183K Buy
+22,861
New +$184K 0.01% 1723

Other funds holding IOVA

Virtu Financial's IOVA Position: Q1 2026 in Review

Virtu Financial opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 285,829 shares worth $1M. The stake represents 0.04% of the portfolio and ranks #308 among its holdings. This is a return to the name: Virtu Financial previously reported a position in IOVA as recently as Q2 2025.

Virtu Financial first reported a position in IOVA in Q4 2017 and has held it in 13 quarters since. The position peaked at $1.34M in Q1 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Virtu Financial held 285,829 shares of Iovance Biotherapeutics worth $1M as of Q1 2026.
  • Iovance Biotherapeutics was a new Virtu Financial position in Q1 2026.
  • Iovance Biotherapeutics made up 0.04% of Virtu Financial's portfolio in Q1 2026, its #308 holding.
  • Virtu Financial first reported a position in Iovance Biotherapeutics in Q4 2017 and has held it in 13 quarters since.
  • Virtu Financial's Iovance Biotherapeutics position peaked at $1.34M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.